ReviewFrontiers in oncology2025
Clinical advances and challenges of anti-angiogenic targeted therapy in gastric cancer.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- MicroRNA-VEGF axis in gastric cancer: a novel therapeutic frontier.Discover oncology · 2026Review
- Banxia xiexin decoction and its bioactive metabolites: multi-targeted mechanisms for suppressing gastric cancer progression, reversing chemoresistance, and remodeling the tumor microenvironment.Frontiers in pharmacology · 2026Review
- From Antibody Drugs to RNA Interference and Nanotherapy: The Evolution and Integration of Targeted Strategies in Gastric Cancer.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) is a malignant neoplasm with one of the highest incidence and mortality rates. However, therapeutic options remain limited for advanced disease. Angiogenesis, a fundamental process in tumor progression, has emerged as a key therapeutic target. To comprehensively evaluate the clinical advancements of anti-angiogenic targeted drugs, this review conducted a systematic search and collation of pertinent literature, While, only ramucirumab achieved regulatory approval for second-line therapy, emerging agents including apatinib and fruquintinib demonstrate significant clinical benefits, particularly in combination with immunotherapy. The review also classifies and summarizes biomarkers with potential predictive value for treatment response, and discusses the current major challenges and potential optimization strategies. This analysis identifies significant gaps in predictive biomarkers and emphasizes that patient stratification and rational combination strategies are essential for optimizing therapeutic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.